Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia

  • Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Pediatric patients with disease refractory to last chemotherapy, relapse after allogeneic hematopoietic stem-cell transplantation (alloHSCT), or second or further relapse have a particularly poor prognosis. Intensive chemotherapy followed by alloHSCT after achieving remission can result in cure for some patients. However, survival is still low with this approach. Thus, additional treatment modalities with acceptable toxicity are needed to improve long-term survival. ...

Download full text files

Export metadata

Metadaten
Author:Lia Gore, Franco LocatelliORCiDGND, Gerhard Zugmaier, Rupert Handgretinger, Maureen M. O’Brien, Peter BaderORCiDGND, Deepa Bhojwani, Paul-Gerhardt SchlegelGND, Catherine A. Tuglus, Arend von StackelbergGND
URN:urn:nbn:de:hebis:30:3-469706
DOI:https://doi.org/10.1038/s41408-018-0117-0
ISSN:2044-5385
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/30190453
Parent Title (English):Blood cancer journal
Publisher:Nature Publishing Group
Place of publication:London [u. a.]
Document Type:Article
Language:English
Year of Completion:2018
Date of first Publication:2018/08/22
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2018/09/18
Tag:Acute lymphocytic leukaemia; Immunotherapy
Volume:8
Issue:9, Art. 80
Page Number:7
First Page:1
Last Page:7
Note:
Rights and permissions: Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
HeBIS-PPN:437850110
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 4.0